We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hyper... Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe. Show more
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of...
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Completed enrollment in the...
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.87 | -3.87700534759 | 22.44 | 23.9764 | 19.83 | 199442 | 21.8801416 | CS |
4 | -7.44 | -25.6463288521 | 29.01 | 32.415 | 19.83 | 179408 | 25.73939299 | CS |
12 | 2.05 | 10.5020491803 | 19.52 | 32.415 | 16.74 | 146934 | 24.75072172 | CS |
26 | 10.53 | 95.3804347826 | 11.04 | 32.415 | 9.41 | 114988 | 21.62764259 | CS |
52 | 2.24 | 11.5882048629 | 19.33 | 32.415 | 9.41 | 97418 | 19.27413126 | CS |
156 | -6.43 | -22.9642857143 | 28 | 32.415 | 7.74 | 98501 | 18.55562829 | CS |
260 | -6.43 | -22.9642857143 | 28 | 32.415 | 7.74 | 98501 | 18.55562829 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions